Immuno-polymeric drugs for prostate cancer therapy

前列腺癌是50岁以上男性最常见的癌症，也是西方社会癌症死亡的第二大原因。当其他干预策略不成功时，多西他赛是化疗的第一线，但30%的患者有严重的副作用。为了解决这个问题，我们将利用一种新的抗体方法直接靶向前列腺肿瘤的多西他赛载体。这增加了肿瘤部位的积累，同时降低了脱靶毒性。

Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.